Under the microscope with Dr Jeffrey A. Borgia, Rush University Medical Center

Industry trends in biomarker developments

Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer.

Currently, Dr Jeffrey A. Borgia, an Associate Professor at Rush University Medical Center in Chicago, IL is refining a simple and cost-effective blood test that will serve as a companion test for lung cancer screening. His lab has developed a risk-stratifying tool that will help guide treatment for patients with suspected lung cancer. His test is based on ‘multiple analyses’ and performed using the Luminex® platform. Its main strength is its high negative predictive value, which is an attractive means to help reduce the large numbers of false positives resulting from low-dose computed tomography-based lung cancer screening protocols. His group is trying to create more effective screening protocols which will reduce the mortality statistics in the near future…